Provided by Tiger Trade Technology Pte. Ltd.

Tyra Biosciences, Inc.

22.03
-1.5100-6.41%
Post-market: 22.170.1400+0.64%19:55 EDT
Volume:1.55M
Turnover:35.06M
Market Cap:1.31B
PE:-9.17
High:23.96
Open:23.63
Low:21.86
Close:23.54
52wk High:40.65
52wk Low:11.82
Shares:59.49M
Float Shares:35.21M
Volume Ratio:0.64
T/O Rate:4.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4031
EPS(LYR):-2.0125
ROE:-45.31%
ROA:-28.46%
PB:3.71
PE(LYR):-10.95

Loading ...

Tyra Bioscience Director Makes Bold Insider Move That Could Signal Big Things Ahead

TIPRANKS
·
Yesterday

Tyra Biosciences Director Rehan Verjee Buys $20,000 of Common Shares

Reuters
·
Yesterday

Tyra Biosciences Price Target Maintained with a $53.00/Share by Wedbush

Dow Jones
·
Sep 10

Tyra Biosciences price target lowered to $30 from $45 at H.C. Wainwright

TIPRANKS
·
Sep 10

U.S. Stocks on the MOVE-Apple, Omnicom, Jersey Mike's Subs

Reuters
·
Sep 10

Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress

Dow Jones
·
Sep 09

Tyra Biosciences Shares Sink After Bladder-Cancer Treatment Causes Adverse Events in Some Patients During Clinical Trial

Dow Jones
·
Sep 09

U.S. Stocks on the MOVE-UGI, Chewy, Cognyte Software

Reuters
·
Sep 09

Tyra Biosciences Tumbles After Cancer Drug Misses Wall Street Expectations

Reuters
·
Sep 09

Tyra Biosciences Reports 79% Response Rate in Phase 2 Bladder Cancer Study of Dabogratinib at 60 Mg Dose

Reuters
·
Sep 09

Tyra Biosciences, - Announces Initial Phase 2 Surf302 Results for Oral Dabogratinib

THOMSON REUTERS
·
Sep 09

Tyra Biosciences to Present at Cantor Global Healthcare Conference 2026

Reuters
·
Sep 09

Analysts Are Bullish on Top Healthcare Stocks: Intuitive Surgical (ISRG), Tyra Bioscience (TYRA)

TIPRANKS
·
Sep 08

U.S. Small Caps Close Up; Tyra Biosciences Climbs Highest

Dow Jones
·
Sep 05

Tyra Biosciences Price Target Maintained with a $45.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 05

Tyra Biosciences: Buy Rating Reiterated as SURF302 Data Upside Beckons; 12‑Month Price Target Maintained at $45

TIPRANKS
·
Sep 04

Tyra Biosciences to Present Initial Phase 2 Surf302 Data for Oral Dabogratinib in Intermediate-Risk Bladder Cancer on Sept. 9

Reuters
·
Sep 04

Tyra Bioscience (TYRA) Gets a Buy from Bank of America Securities

TIPRANKS
·
Aug 11

BofA Adjusts Price Target on Tyra Bioscience to $39 From $42

MT Newswires Live
·
Aug 11

Climb Bio Q2 Net Loss Widens on Pipeline Advancement

Reuters
·
Aug 06